Unicycive Therapeutics (UNCY) Competitors $4.97 +0.28 (+5.97%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$5.00 +0.03 (+0.50%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, AQST, CTOR, and OLMAShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), Aquestive Therapeutics (AQST), Citius Oncology (CTOR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Aquestive Therapeutics Citius Oncology Olema Pharmaceuticals Terns Pharmaceuticals (NASDAQ:TERN) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Does the media favor TERN or UNCY? In the previous week, Unicycive Therapeutics had 4 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 3 mentions for Terns Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.38 beat Terns Pharmaceuticals' score of -0.50 indicating that Unicycive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TERN or UNCY? Terns Pharmaceuticals has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Do analysts recommend TERN or UNCY? Terns Pharmaceuticals presently has a consensus target price of $15.63, suggesting a potential upside of 244.92%. Unicycive Therapeutics has a consensus target price of $60.00, suggesting a potential upside of 1,107.24%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals & insiders have more ownership in TERN or UNCY? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, TERN or UNCY? Unicycive Therapeutics has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.09-4.16Unicycive Therapeutics$680K92.38-$36.73M-$5.10-0.97 Is TERN or UNCY more profitable? Terns Pharmaceuticals' return on equity of -28.81% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -28.81% -27.55% Unicycive Therapeutics N/A -277.30%-61.53% SummaryUnicycive Therapeutics beats Terns Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.29M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.04%P/E Ratio-0.978.9826.9620.11Price / Sales92.38729.50430.20119.79Price / CashN/A159.8036.8257.86Price / Book6.904.517.985.56Net Income-$36.73M$31.26M$3.16B$248.40M7 Day Performance7.11%3.57%2.39%4.67%1 Month Performance-44.78%1.28%2.18%6.64%1 Year Performance4.39%1.08%33.82%21.31% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.114 of 5 stars$4.97+6.0%$60.00+1,107.2%+5.7%$59.29M$680K-0.979High Trading VolumeTERNTerns Pharmaceuticals3.7045 of 5 stars$3.73-2.6%$15.63+318.9%-39.8%$334.50MN/A0.0040HUMAHumacyte2.7442 of 5 stars$2.09-1.4%$11.71+460.5%-54.7%$328.85M$1.57M0.00150News CoverageGap UpPRTAProthena3.0398 of 5 stars$6.07-0.2%$31.50+418.9%-67.7%$327.27M$135.16M0.00130HRTXHeron Therapeutics3.8245 of 5 stars$2.07-3.3%$5.00+141.5%-25.9%$326.49M$144.29M0.00300Positive NewsAMRNAmarin0.6005 of 5 stars$16.22+3.2%$12.00-26.0%+13.8%$325.31M$228.61M0.00360Gap UpHigh Trading VolumePRMEPrime Medicine4.0534 of 5 stars$2.47+2.1%$10.08+308.2%-25.3%$324.30M$3.85M-1.20234Options VolumeHigh Trading VolumeSNDLSNDL3.513 of 5 stars$1.21-1.6%$3.63+199.6%-29.9%$323.21M$671.81M0.002,516AQSTAquestive Therapeutics1.244 of 5 stars$3.31+1.8%$10.14+206.4%+53.3%$322.82M$57.56M0.00160CTORCitius Oncology0.3927 of 5 stars$4.35-3.3%$3.00-31.0%N/A$321.99MN/A0.00N/AOLMAOlema Pharmaceuticals1.7128 of 5 stars$4.26-7.8%$24.50+475.1%-58.0%$316.11MN/A0.0070Positive News Related Companies and Tools Related Companies Terns Pharmaceuticals Alternatives Humacyte Alternatives Prothena Alternatives Heron Therapeutics Alternatives Amarin Alternatives Prime Medicine Alternatives SNDL Alternatives Aquestive Therapeutics Alternatives Citius Oncology Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts